Global Mammography Biopsy Chair Market, by Product Type (Electric, Manual), by Feature (Reclining, Non-Reclining), by End User (Hospitals and Clinics, Ambulatory Surgical Centers, Diagnostic Centers, Others (Cancer Research Institutes, etc.)), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 120.0 Mn in 2022 and is expected to exhibit a CAGR of 4.3% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
Increasing rate of mammogram screening is expected to increase usage of mammography biopsy chairs which is anticipated to augment the global mammography biopsy chair market growth during the forecast period.
For instance, according to the data provided by the Breastcancer.org, a nonprofit organization, in the year 2019, around 6,500 diagnostic mammograms and 28,000 screening mammograms were done per month in the U.S.
Moreover, in April 2020, about 317 screening mammograms and 1,452 diagnostic mammograms were performed in the U.S.
Global Mammography Biopsy Chair Market – Impact of Coronavirus (COVID-19) Pandemic
The coronavirus (COVID-19) pandemic is the most recent outbreak, which was first reported on December 31, 2019 in Wuhan, China. The World Health Organization declared COVID-19 a pandemic on March 11, 2020.
According to the coronavirus disease (COVID-19) weekly epidemiological update by the World Health Organization, over 596,873,121 cases and 6,459,684 deaths due to coronavirus disease (COVID-19) were reported across the globe as of August 26th, 2022
The COVID-19 pandemic has significantly affected several markets across the globe and is also expected to make impact on the global mammography biopsy chair market.
In July 2020, the U.S. Food and Drug Administration (FDA) announced that domestic inspections were anticipated to resume with prioritization on the basis of risk and other factors. Many Mammography Quality Standards Act (MQSA) inspections have resumed under this plan.